**Clinical Need**

Ophthalmologists need a way to achieve sustained dilation of Schlemm’s Canal and distal collector channels in order to increase aqueous humor outflow.

**Background**

Glaucoma Induced Vision Loss is Irreversible

- 90% of vision loss is avoidable
- 12 Million people suffer from Glaucoma in India alone

Leading cause of blindness

Our Target: Schlemm’s Canal

Restoring eye’s natural drainage system to reduce intraocular pressure

**Current Surgical Solutions Shortcomings**

Inadequacies of Contemporary Glaucoma Treatment

- Laser Procedures: Ineffective in highly pigmented eyes
- Incisional Surgery: Invasive and prone to scarring
- Microinvasive Surgery: Unrepeateable and destroys tissue

**Solution Concept: Hydrogel Injection**

- Direct dilation of distal collector channels
- Preserves natural anatomy
- Potential for unlimited repeatability
- No additional operative difficulty
- Likely lower price than implants
- Existing evidence of viscoelastic dilation

**Clinical Value Proposition**

Establishing A Means of Sustained Dilation Will...

1. Increase longevity of IOP reduction
2. Decrease the number of medications patients require
3. Decrease the number of total operations for glaucoma

**Economic Value Proposition**

- **Glaucoma Intervention Market in the United States**
  - 132,000 procedures
  - $5,450 avg cost of MIGS
  - 46% of Glaucoma market is MIGS
  - **$331M**

- **Glaucoma Intervention Market in India**
  - 750,000 procedures
  - $240 avg cost of MIGS
  - 46% of Glaucoma market is MIGS
  - **$83M**

**Milestones**

1. **Concept De-Risking**
   - Completed benchtop testing determining ideal curability of gel
2. **Regulatory Classification**
   - Class III PMA using Hydrus Microstent as Reference device
3. **Applicator Prototyped**
   - Mechanical syringe applicator optimizes surgeon control